Molecular Biology Program
The Simon Powell Lab
The major theme of our work is how DNA repair processes are disrupted in human cancers and how this can be exploited therapeutically. The biologically significant DNA damage caused by ionizing radiation and a number of cytotoxic drugs requires double-strand break repair for survival. We have largely focused on the role of double-strand break repair and homologous recombination in particular.
Bindra RS, Goglia AG, Jasin M, Powell SN. Development of an assay to measure mutagenic non-homologous end-joining repair activity in mammalian cells. Nucleic Acids Res. 2013 Jun 1;41(11):e115. doi: 10.1093/nar/gkt255. Epub 2013 Apr 12.
Singh M, Hunt CR, Pandita RK, Kumar R, Yang CR, Horikoshi N, Bachoo R, Serag S, Story MD, Shay JW, Powell SN, Gupta A, Jeffery J, Pandita S, Chen BP, Deckbar D, Löbrich M, Yang Q, Khanna KK, Worman HJ, Pandita TK. Lamin A/C depletion enhances DNA damage-induced stalled replication fork arrest. Mol Cell Biol. 2013 Mar;33(6):1210-22. doi: 10.1128/MCB.01676-12. Epub 2013 Jan 14. PubMed
Chun J, Buechelmaier ES, Powell SN. Rad51 paralog complexes BCDX2 and CX3 act at different stages in the BRCA1-BRCA2-dependent homologous recombination pathway. Mol Cell Biol. 2013 Jan;33(2):387-95. doi: 10.1128/MCB.00465-12. Epub 2012 Nov 12. PubMed
Lok BH, Powell SN. Molecular pathways: understanding the role of Rad52 in homologous recombination for therapeutic advancement. Clin Cancer Res. 2012 Dec 1;18(23):6400-6. doi: 10.1158/1078-0432.CCR-11-3150. Epub 2012 Oct 15. Review.
Lok BH, Carley AC, Tchang B, Powell SN. RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination. Oncogene. 2012 Sep 10. doi: 10.1038/onc.2012.391. [Epub ahead of print] [PMID: 22964643].
Simon N. Powell, MD, PhD
- Molecular biologist Simon Powell investigates DNA replication and recombination, chromosome dynamics, and human genetics.
- PhD, MD, University of London
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Simon N. Powell discloses the following relationships and financial interests:
PharmaPier US LLC
Provision of Services (uncompensated)
Varian Medical Systems
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.